Royalty Pharma plc
http://www.royaltypharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Royalty Pharma plc
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
Stock Watch: Cytokinetics – From Certain Villain To Possible Hero
Investors’ euphoria on Cytokinetics’ positive Phase III study may be tempered by its high debt, pass-through royalties, entrenched competition and the FTC in the terms of any transaction.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Cypress Bioscience, Inc. (Cellatope Corporation
- Proprius Pharmaceuticals, Inc.)
- Ramius LLC
- Royalty Pharma AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice